Clinical trials: Anticoagulant
Venous Thromboembolism, Anticoagulants
Apixaban for Extended Anticoagulation (APIDULCIS)
The study aims at optimizing the long-term and extended management of patients with a first episode of venous thromboembolism (proximal deep vein thrombosis with or without pulmonary embolism) (VTE).
- Trial name
- APIDULCIS (NCT03678506)
- Testing
- Apixaban
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- Arianna Anticoagulazione Foundation
Stroke, Systemic Embolism
NOAC Portuguese Real World Study
To determine if there is any difference in the effectiveness and safety outcomes of patients with NVAF newly treated with apixaban, dabigatran, rivaroxaban and vitamin K antagonists
- Conditions
- Stroke, Systemic Embolism, Major Bleeding
- Trial name
- NCT04808934
- Testing
- Apixaban, dabigatran, rivaroxaban
- Sponsor
- Pfizer
Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use, Atrial Fibrillation
Evaluation of Oral Anticoagulation With Vitamin K Antagonists - The thrombEVAL Study Programme
Since decades, oral anticoagulation (OAC) with vitamin K antagonists (VKA) is an established therapy for both prevention and treatment of thromboembolism in daily clinical routine.
- Conditions
- Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use, Atrial Fibrillation, Venous Thromboembolism
- Trial name
- thrombEVAL (NCT01809015)
- Where
- Germany
- Volunteers
- 2,318 people
- Sponsor
- Johannes Gutenberg University Mainz
Ischemic Stroke
Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance
The purpose of this study is to determine whether Magnetic Resonance Imaging may predict the risk of Intracerebral Hemorrhage for patients with ischemic stroke who receive indefinite oral anticoagulation
- Trial name
- HERO (NCT02238470)
- Testing
- oral anticoagulants
- Where
- 30 sites in Italy, Spain
- Volunteers
- 1,000 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Venous Thromboembolic Disease
Comparative Study of the Hemorrhagic Risk in Patients Over 75 Years of Age Taking Enoxaparin
Elderly subjects are at greater risk of thrombophlebitis than the general population, but also of bleeding when anticoagulant therapy is initiated.
- Trial name
- ENOX-VTD-H (NCT05150314)
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- University Hospital, Strasbourg, France
Venous Thromboembolism
CoMbination of Data From European Cohorts as Part of the European MORPHEUS Project [HORIZON-HLTH-2022-11-01] - "MC-MORPHEUS".
Combine clinical, biological and morphological data from 14 French and European cohorts into a single database.
- Trial name
- MC-MORPHEUS (NCT07328152)
- Where
- France
- Volunteers
- 20,000 people
- Sponsor
- University Hospital, Brest
Anticoagulant, Pharmacogenetics
Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care
The interdisciplinary collaboration between doctors, nurses and pharmacists, can facilitate the control of patients under treatment with coumarin anticoagulants, increasing their safety and effectiveness.
- Conditions
- Anticoagulant, Pharmacogenetics, Community Pharmacy Services, Drug Utilization Review
- Trial name
- NCT03154489
- Testing
- acenocoumarol, control
- Where
- Spain
- Volunteers
- 204 people
- Sponsor
- Universidad San Jorge
Atrial Fibrillation, Vascular Risk
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)
The purpose of this study is to determine if the combination of Clopidogrel 75mg once daily (od) plus aspirin at 100mg daily (recommended dose) is as effective as oral anticoagulation therapy with a lower risk of bleeding in…
- Trial name
- NCT00243178
- Testing
- clopidogrel (SR25990C)
- Where
- 32 sites in United States, Australia and 30 more
- Volunteers
- 6,706 people
- Sponsor
- Sanofi
Atrial Fibrillation
Clinical Trial to Improve Treatment With Blood Thinners in Patients With Atrial Fibrillation
To determine whether a comprehensive evaluation and customized multilevel educational interventions will increase the rate of use of oral anticoagulants and the adherence and persistence of use in patients with atrial…
- Trial name
- IMPACT-AF (NCT02082548)
- Testing
- Educational Intervention
- Where
- 5 sites in Argentina, Brazil and 3 more
- Volunteers
- 2,374 people
- Sponsor
- Duke University
Atrial Fibrillation, Coronary Artery Disease
Comparison Between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention
A prospective, multicenter, 1:1 randomized, investigator initiated study. Goal of this study is to examine the safety of uninterrupted periprocedural DOAC use.
- Conditions
- Atrial Fibrillation, Coronary Artery Disease, Anticoagulants
- Trial name
- SLIM-2 (NCT04977076)
- Testing
- Uninterrupted DOAC use, Interrupted DOAC use
- Where
- Netherlands
- Volunteers
- 1,270 people
- Sponsor
- Zuyderland Medisch Centrum
Non-valvular Atrial Fibrillation
Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation
In a population of patients with non-valvular atrial fibrillation (NVAF), and treated with oral anticoagulants (OAC) in routine clinical practice in England, this study will describe patients treated with each OAC, and to…
- Trial name
- NCT03002740
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism, Brain Tumors
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
In patients with malignant glioma, to determine the efficacy of prophylaxis with LMWH (dalteparin) compared to placebo, both commenced beyond the immediate postoperative period, for the prevention of VTE.
- Trial name
- NCT00135876
- Testing
- dalteparin
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 512 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Antithrombinemia
Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals
Antithrombin (AT) is a physiological inhibitor of the coagulation cascade. In therapeutics, its presence in sufficient quantities is necessary for the pharmacological activity of unfractionated heparin (UFH) and partially…
- Trial name
- EPPATHUS (NCT07276074)
- Where
- France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Strasbourg, France
Atrial Fibrillation
Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate…
- Trial name
- WARFA (NCT02017197)
- Testing
- Marevan®, generic warfarin #1, generic warfarin #2
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- Federal University of São Paulo
Anticoagulants; Circulating, Hemorrhagic Disorder
MEdication Counselling Models for Outpatient oRal antIcoaguLation
The goal of this clinical trial is to investigate whether telepharmacy-led counselling can improve medication adherence, knowledge, and hospitalisation/mortality compared with pharmacist-led counselling in adult outpatients…
- Trial name
- MEMORIAL (NCT06290440)
- Testing
- Telepharmacy-led counselling, Pharmacist-led counselling
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Gia Dinh People Hospital
Atrial Fibrillation (AF)
Episodic Future Thinking to Improve Anticoagulant Adherence in Atrial Fibrillation
The purpose of this study is to assess the effectiveness of Episodic Future Thinking (EFT) on improving medication adherence in atrial fibrillation (AF) patients taking oral anticoagulants.
- Trial name
- NCT07174778
- Testing
- Episodic future thinking, attention control
- Where
- 2 sites in China
- Volunteers
- 68 people
- Sponsor
- Jiawen You
Wound Bleeding
Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B
The goal of this clinical trial is to test if the study drug, BXP154B works to stop bleeding from a minor wound in patients that are on apixaban for anticoagulant therapy.
- Trial name
- NCT06205615
- Testing
- BXP154B, Punch Biopsy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Bio 54, LLC
Healthy Volunteers, Drug Drug Interactions
Human Cytochrome P450 4F Enzymes and Drug Interactions
Drug-drug interactions play an important role in clinical adverse events due to the prevalence of multi-drug therapy. Co-administration of warfarin and a statin has expanded substantially in the US over the last decades.
- Trial name
- NCT01250535
- Testing
- Warfarin, Lovastatin
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Deep Venous Thrombosis, Pulmonary Embolism
The DARE Warfarin CER Study
Approximately half a million Americans annually experience venous thromboembolic disease, including deep venous thrombosis (DVT) and pulmonary embolism (PE).
- Trial name
- NCT03271450
- Testing
- Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days)
- Where
- United States
- Volunteers
- 416,000 people
- Sponsor
- Brigham and Women's Hospital
Atrial Fibrillation (AF), Stroke
Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation
Atrial fibrillation (AF) is the most common arrhythmia, significantly increasing the risk of stroke, heart failure, hospitalization and death in patients.
- Conditions
- Atrial Fibrillation (AF), Stroke, Hemorrhage, Frailty
- Trial name
- CLEAR-AF (NCT07441382)
- Testing
- catheter ablation combined with LAAO (Left Atrial Appendage Occlusion), Atrial Fibrillation Radiofrequency Ablation Only
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Guangdong Provincial People's Hospital